semaglutide and retatrutide vs. Retatrutide: A Comparison Retatrutide vs. Ozempic: The Triple

Becky Yung, Florence Yau, Anki Miu, and Rebecca Chau for administrative support to the project

Market Scope Market Dynamics Drivers Rising Prevalence of Type 2 Diabetes and Obesity A major factor driving the adoption of GLP-1 analogues is the rise in diabetes and obesity cases worldwide

Weight in pediatric patients was 95 th percentile using growth chart assessments

These companies generated tens of billions in revenue from these medications while allegedly downplaying severe adverse effects that went far beyond the bloating , constipation , and nausea listed on standard warning labels

Switching between formulations is possible under physician guidance, but patients should not use both forms simultaneously

Moreover, the anti-inflammatory effect of liraglutide via regulating ER stress was abolished by GLP-1R siRNA